Benefits of cardiac resynchronization therapy
This article has no abstract so we have provided the first paragraph of the full text.
Results from the Cardiac Resynchronization—Heart Failure (CARE-HF) study support the use of implantable cardiac-resynchronization devices in patients with heart failure due to left-ventricular systolic dysfunction and cardiac dyssynchrony. As anticipated, symptoms, left-ventricular function and quality of life improved, and plasma concentrations of natriuretic peptides declined in patients receiving this intervention. Importantly, the trial also revealed that these benefits were accompanied by a substantial reduction in the risk of death or complications.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mathematical physics Added dimensions to grain growthNature News and Views (26 Apr 2007)
DisSARMing Toll-like receptor signalingNature Immunology News and Views (01 Oct 2006)
